CIAPIN1 confers multidrug resistance by upregulating the expression of MDR-1 and MRP-1 in gastric cancer cells

Cancer Biology and Therapy

Volumn 5, Issue 3, 2006, Pages 261-266

  Hao, Zhiming ^a   Li, Xiaohua ^a   Qiao, Taidong ^a   Du, Rui ^a   Hong, Liu ^a   Fan, Daiming ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Anticancer drugs; Apoptosis; CIAPIN1; Gastric cancer; MDR 1; MRP 1; Multidrug resistance

Indexed keywords

APOPTOSIS INHIBITOR; COMPLEMENTARY DNA; CYTOKINE INDUCED APOPTOSIS INHIBITOR 1; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; DOWN REGULATION; DRUG SENSITIVITY; IN VITRO STUDY; MULTIDRUG RESISTANCE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; STOMACH CANCER; UPREGULATION; WESTERN BLOTTING;

EID: 33646428954     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.5.3.2381     Document Type: Article

References (46)

1. Fan D, Zhang X, Chen X, Mou Z, Hu J, Zhou S, Ding J, Wu K. Bird's-eye view on gastric cancer research of the past 25 years. J Gastroenterol Hepatol 2005; 20:360-5.
2. Stavrovskaya AA. Cellular mechanism of multidrug resistance to tumor cells. Biochemistry (Moscow) 2000; 65:112-6.
3. Banejee D, Mayer-Kuckuk P, Capiaux G, Budak-Alpdogan T, Gorlick R, Bertino JR. Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase. Biochimica Biophysics Acta 2002; 1587:164-73.
4. Larsen AK, Escargueil AE, Skladanowski A. Resistance mechanisms associated with altered intracellular distribution of anticancer agents. Pharmacol Ther 2000; 85:217-29.
5. Ross DD. Novel mechanisms of drug resistance in leukemia. Leukemia 2000; 14:467-73.
6. Litman T, Druley TE, Stein WD, Bates SE. From MDR to MXR: New understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 2001; 58:931-59.
7. Narasaki F, Oka M, Nakano R, Ikeda K, Fukuda M, Nakamura T, Soda H, Nakagawa M, Kuwano M, Kohno S. Human canalicular multispecific organic anion transporter (cMOAT) is expressed in human lung, gastric, and colorectal cancer cells. Biochem Biophys Res Commun 1997; 240:606-11.
8. Nakamura T, Oka M, Aizawa K, Soda H, Fukuda M, Terashi K, Ikeda K, Mizuta Y, Noguchi Y, Kimura Y, Tsuruo T, Kohno S. Direct interaction between a quinoline derivative, MS-209, and multidrug resistance protein (MRP) in human gastric cancer cells. Biochem Biophys Res Commun 1999; 255:618-24.
9. Tomonaga M, Oka M, Narasaki F, Fukuda M, Nakano R, Takatani H, Ikeda K, Terashi K, Matsuo I, Soda H, Cowan KH, Kohno S. The multidrug resistance-associated protein gene confers drug resistance in human gastric and colon cancers. Jpn J Cancer Res 1996; 87:1263-70.
10. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: A link between cancer genetics and chemotherapy. Cell 2002; 108:153-64.
11. Inoue S, Salah-Eldin AE, Omoteyama K. Apoptosis and anticancer drug resistance. Hum Cell 2001; 14:211-21.
12. Shibuya H, Kato Y, Saito M, Isobe T, Tsuboi R, Koga M, Toyota H, Mizuguchi J. Induction of apoptosis and/or necrosis following exposure to antitumour agents in a melanoma cell line, probably through modulation of Bcl-2 family proteins. Melanoma Res 2003; 13:457-64.
13. Grossman D, Altieri DC. Drug resistance in melanoma: Mechanisms, apoptosis, and new potential therapeutic targets. Cancer Metastasis Rev 2001; 20:3-11.
14. Siddik ZH. Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene 2003; 22:7265-79.
15. Salinas AE, Wong MG. Glutathione S-transferases - A review. Curr Med Chem 1999; 6:279-309.
16. Waxman DJ. Glutathione S-transferases: Role in alkylating agent resistance and possible target for modulation chemotherapy - A review. Cancer Res 1990; 50:6449-54.
17. Tew KD. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 1994; 54:4313-20.
18. Fan K, Fan D, Cheng L, Li C. Expression of multidrug resistance related markers in gastric cancer. Anticancer Res 2000; 20:4809-14.
19. Zhao Y, You H, Liu F, An H, Shi Y, Yu Q, Fan D. Differentially expressed gene profiles between multidrug resistant gastric adenocarcinoma cells and their parental cells. Cancer Lett 2002; 185:211-8.
20. Shibayama H, Takai E, Matsumura I, Kouno M, Morii E, Kitamura Y, Takeda J, Kanakura Y. Identification of a cytokine-induced antiapoptosis molecule anamorsin essential for definitive hematopoiesis. J Exp Med 2004; 199:581-92.
21. Hao Z, Qiao T, Jin X, Li X, Gao J, Fan D. Preparation and characterization of a specific monoclonal antibody against CIAPIN1. Hybridoma 2005; 24:141-5.
22. Yamaue H, Tanimura H, Noguchi K, Hotta T, Tani M, Tsunoda T, Iwahashi M, Tamai M, Iwakura S. Chemosensitivity testing of fresh human gastric cancer with highly purified tumor cells using the MTT assay. Br J Cancer 1992; 66:794-9.
23. Yamaue H, Tani M, Onishi H, Kinoshita H, Nakamori M, Yokoyama S, Iwahashi M, Uchiyama K. Locoregional chemotherapy for patients with pancreatic cancer intra-arterial adjuvant chemotherapy after pancreatectomy with portal vein resection. Pancreas 2002; 25:366-72.
24. Shi Y, Han Y, Wang X, Zhao Y, Ning X, Xiao B, Fan D. MGr1-Ag is associated with multidrug-resistant phenotype of gastric cancer cells. Gastric Cancer 2002; 5:154-9.
25. Malugin A, Kopecková P, Kopecek J. HPMA Copolymer-bound doxorubicin induces apoptosis in human ovarian carcinoma cells by a Fas-independent pathway. Mol Pharmaceutics 2004; 1:174-82.
26. Hao Z, Li X, Qiao T, Zhang J, Shao X, Fan D. Distribution of CIAPIN1 in normal fetal and adult human tissues. J Histochem Cytochem; In press.
27. Glavinas H, Krajcsi P, Cserepes J, Sarkadi B. The role of ABC transporters in drug resistance, metabolism and toxicity. Curr Drug Delivery 2004; 1:27-42.
28. Lucia MB, Golotta C, Rutella S, Rastrelli E, Savarino A, Cauda R. Atazanavir inhibits P-glycoprotein and multidrug-associated protein efflux activity. J Acquir Immune Defic Syndr 2005; 39:635-7.
29. Xiao B, Shi YQ, Zhao YQ, You H, Wang ZY, Liu XL, Yin F, Qiao TD, Fan DM. Transduction of Fas gene or Bcl-2 antisense RNA sensitizes cultured drug resistant gastric cancer cells to chemotherapeutic drugs. World J Gastroenterol 1998; 4:421-25.
30. Zhao Y, Xiao B, Chen B, Qiao T, Fan D. Upregualtion of drug sensitivity of multidrug-resistant SGC7901/VCR human gastric cancer cells by Bax gene transduction. Chin Med J (Engl) 2000; 113:977-80.
31. Yin F, Shi YQ, Zhao WP, Xiao B, Miao JY, Fan DM. Suppression of P-gp induced multiple drug resistance in a drug resistant gastric cancer cell line by overexpression of Fas. World J Gastroenterol 2000; 6:664-70.
32. Guo C, Ding J, Yao L, Sun L, Lin T, Song Y, Fan D. Tumor suppressor gene Runx3 sensitizes gastric cancer cells to chemotherapeutic drugs by downregulating Bcl-2, MDR-1 and MRP-1. Int J Cancer 2005; 116:155-60.
33. Du J, Pan Y, Shi Y, Guo C, Jin X, Sun L, Liu N, Qiao T, Fan D. Overexpression and significance of prion protein in gastric cancer and multidrug-resistant gastric cancer cell line SGC7901. Int J Cancer 2005; 113:213-20.
34. Shi Y, Zhai H, Wang X, Han Z, Liu C, Lan M, Du J, Guo C, Zhang Y, Wu K, Fan D. Ribosomal proteins S13 and L23 promote multidrug resistance in gastric cancer cells by suppress drug-induced apoptosis. Exp Cell Res 2004; 296:337-46.
35. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74:609-19.
36. Chin KV, Ueda K, Pastan I, Gottesman MM. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 1992; 255:459-62.
37. Wang Q, Beck WT. Transcriptional suppression of multidrug resistance-associated protein (MRP) gene expression by wild-type p53. Cancer Res 1998; 58:5762-9.
38. Zhan M, Yu D, Lang A, Li L, Pollock RE. Wild type p53 sensitizes soft tissue sarcoma cells to doxorubicin by downregulating multidrug resistance-1 expression. Cancer 2001; 92(6):1556-66.
39. Fukushima Y, Oshika Y, Tokunaga T, Hatanaka H, Tomisawa M, Kawai K, Ozeki Y, Tsushida T, Kijima H, Yamazaki H, Ueyama Y, Tamaoki N, Miura S, Nakamura M. Multidrug resistance-associated protein (MRP) expression is correlated with expression of aberrant p53 protein in colorectal cancer. Eur J Cancer 1999; 35:935-8.
40. Sullivan GF, Yang JM, Vassil A, Yang J, Bash-Babula J, Hait WN. Regulation of expression of the multidrug resistance protein MRP1 by p53 in human prostate cancer cells. J Clin Invest 2000; 105:1261-7.
41. Li ZH, Zhu YJ, Lit XT. Wild-type p53 gene increases MDR1 gene expression but decreases drug resistance in an MDR cell line KBV200. Cancer Lett 1997; 119:177-84.
42. Oka M, Kounoura K, Narasaki F, Sakamoto A, Fukuda M, Matsuo I, Ikeda K, Tsurutani J, Ikuno N, Omagari K, Mizuta Y, Soda H, Gudas JM, Kohno S. P-glycoprotein is positively correlated with p53 protein accumulation in human colorectal cancers. Jpn J Cancer Res 1997; 88:738-42.
43. Zhou G, Kuo MT. Wild-type p53-mediated induction of rat mdr1b expression by the anticancer drug daunorubicin. J Biol Chem 1998; 273:15387-94.
44. Bähr O, Wick W, Weller M. Modulation of MDR/MRP by wild-type and mutant p53. J Clin Invest 2001; 107:643-5.
45. Zhang QY, Lu YY, Li Z, Li WM, Cui JT, Xie SH, Deng DR. p53 gene mutation in Chinese gastric carcinoma cell lines. Shengwu Huaxue Zazhi (in Chinese with English abstract) 1995; 11:311-5.
46. Jiang XH, Wong BC, Lin MC, Zhu GH, Kung HF, Jiang SH, Yang D, SK Lam. Functional p53 is required for triptolide-induced apoptosis and Ap-1 and nuclear factor - KappaB activation in gastric cancer cells. Oncogene 2001; 20:8009-18.